| 0.85 -0.018 (-2.02%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.16  |
1-year : | 1.29 |
| Resists | First : | 0.99 |
Second : | 1.11 |
| Pivot price | 0.93 |
|||
| Supports | First : | 0.81 |
Second : | 0.67 |
| MAs | MA(5) : | 0.89 |
MA(20) : | 0.95 |
| MA(100) : | 0.82 |
MA(250) : | 2.66 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 21.3 |
D(3) : | 28.9 |
| RSI | RSI(14): 44 |
|||
| 52-week | High : | 7.28 | Low : | 0.63 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ATYR ] has closed above bottom band by 11.6%. Bollinger Bands are 3.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.9 - 0.91 | 0.91 - 0.91 |
| Low: | 0.81 - 0.82 | 0.82 - 0.82 |
| Close: | 0.84 - 0.85 | 0.85 - 0.86 |
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Sun, 15 Mar 2026
aTyr Pharma (NASDAQ:ATYR) Upgraded at Wall Street Zen - MarketBeat
Thu, 12 Mar 2026
aTyr Pharma (NASDAQ: ATYR) asks shareholders to double authorized shares to 340M - Stock Titan
Thu, 12 Mar 2026
aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting - MarketBeat
Thu, 05 Mar 2026
Atyr Pharma: Q4 Earnings Snapshot - WHAS11
Thu, 05 Mar 2026
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update - GlobeNewswire
Fri, 20 Feb 2026
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 9.56e+007 (%) |
| Held by Institutions | 1.4 (%) |
| Shares Short | 21,330 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.696e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -40 % |
| Return on Assets (ttm) | 856.3 % |
| Return on Equity (ttm) | -51.2 % |
| Qtrly Rev. Growth | 190000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -193.06 |
| EBITDA (p.s.) | -1.07196e+008 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -62 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.68 |
| Dividend | 0 |
| Forward Dividend | 1.988e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|